Beta Bionics (BBNX) Form 144 Files Proposed Sale of 9,900 Shares

Rhea-AI Filing Summary

Form 144 notice for Beta Bionics, Inc. (BBNX): The filing reports a proposed sale of 9,900 common shares through Merrill Lynch on 09/08/2025 on NASDAQ with an aggregate market value of $209,152.15. The shares were acquired the same day as stock options from the issuer and paid in cash. The filing lists total shares outstanding as 43,470,125. Recent insider sales by Stephen Feider are included: 1,497 shares on 06/02/2025 for $26,783.06; 5,587 on 08/19/2025 for $95,171.78; 4,413 on 08/22/2025 for $75,082.65; and 100 on 09/05/2025 for $2,100.00. Several standard filer and issuer identifier fields are blank in the provided content.

Positive

• Transparency: The Form 144 discloses the number of shares, sale date, broker, and aggregate market value.
• Insider compliance: The filer includes the Rule 144 representation and references Rule 10b5-1 language.

Negative

• Missing identifiers: Key filer and issuer identifier fields (CIK/CCC and issuer name/address) are blank in the provided content.
• Limited materiality: The sale value (~$209k) is small relative to the stated 43,470,125 shares outstanding, suggesting minimal market impact.

Insights

Securities Analyst

TL;DR: Routine Form 144 disclosure showing an insider sale of newly acquired option shares; not clearly material to company fundamentals.

The notice documents a proposed sale of 9,900 common shares acquired via stock options on the same date, indicating immediate disposition of option proceeds rather than long-term retention. Aggregate value is modest relative to the reported 43.47 million shares outstanding, suggesting limited dilution or market impact. The filing lists prior small insider sales by Stephen Feider over the past three months. Several filer/issuer identifier fields are missing from the provided extract, reducing traceability.

Corporate Governance Expert

TL;DR: Disclosure follows Rule 144 mechanics; missing identifier fields limit verification but content shows standard insider sale activity.

The form indicates the seller represents no undisclosed material nonpublic information and references Rule 10b5-1 language, which is customary. The immediate sale of option shares and repeated small dispositions by the named individual are consistent with routine insider liquidity actions. Absence of explicit filer CIK/CCC and issuer address in the extract is a documentation gap that should be corrected for full transparency.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 6002 El Tordo 2nd FL PO Box 7297 Rancho Santa Fe CA 92067	9900	209152.15	43470125	09/08/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/08/2025	Stock Options	Issuer			9900	09/08/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Stephen Feider 11 HUGHES Irvine CA 92618	Common	09/05/2025	100	2100.00
Stephen Feider 11 HUGHES Irvine CA 92618	Common	08/22/2025	4413	75082.65
Stephen Feider 11 HUGHES Irvine CA 92618	Common	08/19/2025	5587	95171.78
Stephen Feider 11 HUGHES Irvine CA 92618	Common	06/02/2025	1497	26783.06

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does this Form 144 for Beta Bionics (BBNX) report?

It reports a proposed sale of 9,900 common shares via Merrill Lynch on 09/08/2025 with an aggregate market value of $209,152.15 to be executed on NASDAQ.

How were the 9,900 shares acquired according to the filing?

The filing states the shares were acquired on 09/08/2025 via stock options from the issuer and payment was in cash.

Are there recent insider sales disclosed in this filing?

Yes. The filing lists sales by Stephen Feider: 1,497 shares on 06/02/2025 for $26,783.06; 5,587 on 08/19/2025 for $95,171.78; 4,413 on 08/22/2025 for $75,082.65; and 100 on 09/05/2025 for $2,100.00.

Does the filing indicate material nonpublic information?

The signer represents they do not know any material adverse nonpublic information; the form contains the standard attestation but no additional disclosures of material nonpublic information.

Is the disclosed sale likely to materially affect BBNX shares outstanding?

No. The disclosed sale of 9,900 shares is small versus the reported 43,470,125 shares outstanding, indicating limited dilution or market impact.